Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
32
XLO Quote, Financials, Valuation and Earnings
Last price:
$0.67
Seasonality move
:
-27.24%
Day range:
$0.65 - $0.68
52-week range:
$0.62 - $1.70
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.00x
P/B ratio:
5.19x
Volume:
155.4K
Avg. volume:
638.2K
1-year change:
-28.68%
Market cap:
$35.1M
Revenue:
$6.3M
EPS (TTM):
-$0.66
Analysts' Opinion
-
Consensus RatingXilio Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $4.00, Xilio Therapeutics, Inc. has an estimated upside of 198.95% from its current price of $0.67.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $4.00 representing 100% downside risk from its current price of $0.67.
Fair Value
-
According to the consensus of 1 analyst, Xilio Therapeutics, Inc. has 198.95% upside to fair value with a price target of $4.00 per share.
XLO vs. S&P 500
-
Over the past 5 trading days, Xilio Therapeutics, Inc. has underperformed the S&P 500 by -1.88% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Xilio Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Xilio Therapeutics, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Xilio Therapeutics, Inc. reported revenues of $19.1M.
Earnings Growth
-
Xilio Therapeutics, Inc. has grown year-over-year earnings for 10 quarters straight. In the most recent quarter Xilio Therapeutics, Inc. reported earnings per share of -$0.11.
Enterprise value:
-61.4M
EV / Invested capital:
73.77x
Price / LTM sales:
2.00x
EV / EBIT:
--
EV / Revenue:
-1.93x
PEG ratio (5yr expected):
--
EV / Free cash flow:
3.49x
Price / Operating cash flow:
2.05x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$30.1M
Return On Assets:
-56.57%
Net Income Margin (TTM):
-183.91%
Return On Equity:
-606.15%
Return On Invested Capital:
-334.24%
Operating Margin:
-10.12%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | $4.6M | $31.8M | $2.3M | $19.1M | |
| Gross Profit | -$1.9M | $2.9M | $30.1M | $1.9M | $18.7M | |
| Operating Income | -$84.2M | -$64.1M | -$43.8M | -$14.8M | -$1.9M | |
| EBITDA | -$82.2M | -$62.4M | -$42.1M | -$14.4M | -$1.6M | |
| Diluted EPS | -$2.96 | -$1.72 | -$0.66 | -$0.22 | -$0.11 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $105.6M | $142.3M | $64.5M | $63.3M | $124.1M | |
| Total Assets | $120.7M | $157.4M | $77.8M | $74.7M | $133.7M | |
| Current Liabilities | $12.9M | $16.8M | $16.9M | $38M | $56.4M | |
| Total Liabilities | $34.3M | $31.1M | $25.3M | $53.7M | $141.8M | |
| Total Equity | $86.4M | $126.3M | $52.5M | $21M | -$8.1M | |
| Total Debt | $20.7M | $19.2M | $13.4M | $7.3M | $6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$73.4M | -$17.6M | -$17.2M | -$13.7M | -$17.5M | |
| Cash From Investing | -$995K | -$30K | -$429K | -$9K | -- | |
| Cash From Financing | -$4.9M | $19.4M | $60.1M | -$3K | -$285K | |
| Free Cash Flow | -$74.4M | -$17.7M | -$17.6M | -$13.7M | -$17.5M | |
XLO
Sector
Market Cap
$35.1M
$27.9M
Price % of 52-Week High
39.35%
51.04%
Dividend Yield
0%
0%
Shareholder Yield
-136.98%
-1.49%
1-Year Price Total Return
-28.68%
-16.66%
Beta (5-Year)
--
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.67
200-day SMA
Sell
Level
$0.75
Bollinger Bands (100)
Sell
Level
0.68 - 0.8
Chaikin Money Flow
Buy
Level
88.6K
20-day SMA
Sell
Level
$0.71
Relative Strength Index (RSI14)
Sell
Level
37.93
ADX Line
Buy
Level
13.45
Williams %R
Neutral
Level
-67.3367
50-day SMA
Sell
Level
$0.75
MACD (12, 26)
Buy
Level
0.12
25-day Aroon Oscillator
Sell
Level
-80
On Balance Volume
Neutral
Level
159.5K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-9.192)
Sell
CA Score
(Annual)
Level (-4.9046)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (6.8222)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Xilio Therapeutics, Inc. operates as a biotechnology company. It focuses on harnessing the immune system to achieve deep and durable clinical responses in cancer. The company uses its proprietary geographically precise solutions platform to rapidly engineer novel molecules, including cytokines and other biologics. Xilio Therapeutics was founded by John C. Williams and Ulrich Rodeck in June 2015 and is headquartered in Waltham, MA.
Stock Forecast FAQ
In the current month, XLO has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The XLO average analyst price target in the past 3 months is $4.00.
-
Where Will Xilio Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Xilio Therapeutics, Inc. share price will rise to $4.00 per share over the next 12 months.
-
What Do Analysts Say About Xilio Therapeutics, Inc.?
Analysts are divided on their view about Xilio Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Xilio Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $4.00.
-
What Is Xilio Therapeutics, Inc.'s Price Target?
The price target for Xilio Therapeutics, Inc. over the next 1-year time period is forecast to be $4.00 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is XLO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Xilio Therapeutics, Inc. is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of XLO?
You can purchase shares of Xilio Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Xilio Therapeutics, Inc. shares.
-
What Is The Xilio Therapeutics, Inc. Share Price Today?
Xilio Therapeutics, Inc. was last trading at $0.67 per share. This represents the most recent stock quote for Xilio Therapeutics, Inc.. Yesterday, Xilio Therapeutics, Inc. closed at $0.67 per share.
-
How To Buy Xilio Therapeutics, Inc. Stock Online?
In order to purchase Xilio Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get XLO Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
XLO
Sector
P/E ratio
--
23.85x
PEG ratio
--
-0.01x
P/B ratio
5.19x
1.81x
Price / LTM sales
2.00x
1.58x
Growth Metrics
XLO
Sector
Revenue growth
742.51%
4.62%
Earnings growth
48.85%
10.5%
Revenue (5-year growth)
--
6.5%
Earnings forecast
$0.37
-$0.21
Profitability
XLO
Sector
Profitability FY 2024
$4.7M
$3.6M
Return on invested capital
-334.24%
-31.87%
Return on assets
-56.57%
-28.18%
Return on equity
-606.15%
-37.63%
Earnings Date
Last Earnings Date
Nov
8
Next Earnings Date
Dec
21
Estimated Next Earnings Date
Mar
22
Balance Sheet
XLO
Sector
Total cash
$103.8M
$26.4M
Short term investments
--
$25.7M
Total assets
$71.1M
$76.9M
Long term debt
$6M
$3.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
